Patient-Derived Organoids as a Platform to Decipher and Overcome Radioresistance: From the Tumor Microenvironment to Radiosensitizer Discovery

Patient-derived organoids (PDOs) preserve patient genotypes and 3D architecture, offering a useful platform to investigate mechanisms of radioresistance and test radiosensitizers. We outline an end-to-end workflow—model establishment, multi-omics profiling, pharmacologic screening, and in vivo confi...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Dashan Yin, Xiujuan Hong, Xiaoqi Wang, Wenjia Ding, Chenli Wang, Jin Qian, Yi Zhou, Chuan Sun, Zhibing Wu
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2025-12-01
Rangatū:	Current Oncology
Ngā marau:	patient-derived organoids (PDOs) radioresistance radiosensitizers radiotherapy (RT) tumor microenvironment (TME) cancer stem cells (CSCs)
Urunga tuihono:	https://www.mdpi.com/1718-7729/32/12/680
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!